Unified Patent Court (UPC) analytics are now available. Check here

EP3302565

PFIZER
Application Number
EP16726192A
Filing Date
May 24, 2016
Status
Revoked
Oct 25, 2024
Grant Date
Nov 6, 2019
External Links
Slate, Register, Google Patents
Similar Patents facing opposition

Biblio Summary

The patent EP3302565B1 was granted on Nov 6, 2019 by Pfizer The patent is currently Revoked.

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKAug 6, 2020ADMISSIBLE
SYNTHONAug 6, 2020ADMISSIBLE
GALENICUM HEALTH SLUAug 5, 2020ADMISSIBLE
HEXALAug 5, 2020ADMISSIBLE
HOFFMANN EITLEAug 4, 2020ADMISSIBLE
TEVA PHARMACEUTICAL INDUSTRIESAug 4, 2020ADMISSIBLE

Patent citations in opposition refer to prior patents or publications that may challenge the validity of a contested patent. These references help assess whether the invention is truly novel or overlaps with existing intellectual property.

Citation PhasePatent NumberPatent LinkCited Text
OppositionEP2958916B1
N/A
OppositionUS2003149001
N/A
OppositionUS2007141141
N/A
OppositionUS2009214645
N/A
OppositionUS2006183779
N/A
OppositionWO2013092497
N/A
OppositionWO2014128588
N/A
OppositionWO2013078264
N/A
OppositionJP2013189455
N/A
OppositionWO2015022609
N/A

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.